Evaxion Biotech’s CEO for the past nine years, Lars Staal Wegner, will be replaced by the highly experienced Per Norlén, who will continue the company’s
Audientes, which develops and produces hearing aids for third world countries, has adjusted its strategy towards more profitable operations and is therefore significantly lowering its
Evaxion Biotech recently announced that it has selected the sexually transmitted disease gonorrhea as the second target for the EVX-B2 vaccine candidate, which is based
The ViroGates share has shown strong performance with an increase of almost 100% this year (November 5, 2021), driven by customer progress, solid clinical sales
With good prospects for Orviglance(previously known as Mangoral) we expect coming phase 3 data due in H1’2022 will have significant positive impact on the share
Evaxion Biotechis a Danish pharmaceutical company listed at Nasdaq Stock Market in the US. The company uses an AI-immunology platform decoding the immune system to
Hansa Biopharma is a biopharmaceutical company with headquarter in Lund, Sweden. The company develops and commercializes treatments for patients with immunological conditions and rare immunoglobulin
ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body. It is possible to measure
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.